neoplasm
• mutants develop mammary tumors
(J:153233)
• nearly 40% of mammary tumors are microacinar, with the remainder of tumors showing various other morphologies including, papillary, squamous, epithelial-mesenchymal-transition (EMT) type, solid, adenocarcinoma and tumors with mixed population of various types of tumors
(J:153233)
• the squamous/EMT subgroup of tumors shares attributes of human triple-negative breast cancer and is associated with an increase in risk of metastasis
(J:153233)
• Kras activating mutations are seen in 22.4% of tumors
(J:193362)
• mice with tumors containing a Kras mutation show a reduction in latency compared to mice with tumors without a mutation
(J:193362)
• microacinar type tumors show similar expression profiles to human luminal B tumors
(J:193362)
• epithelial-mesenchymal-transition (EMT) subtype tumors have an elevation in the frequency of activating Kras mutations compared to the other types of tumors seen in mutants and show similar expression profiles to human claudin-low tumors
(J:193362)
|
• pulmonary metastasis is sometimes observed and is associated with the squamous/EMT subgroup of tumors
|
endocrine/exocrine glands
• mammary glands show increased side bud formation at 8 weeks of age
|
• mutants develop mammary tumors
(J:153233)
• nearly 40% of mammary tumors are microacinar, with the remainder of tumors showing various other morphologies including, papillary, squamous, epithelial-mesenchymal-transition (EMT) type, solid, adenocarcinoma and tumors with mixed population of various types of tumors
(J:153233)
• the squamous/EMT subgroup of tumors shares attributes of human triple-negative breast cancer and is associated with an increase in risk of metastasis
(J:153233)
• Kras activating mutations are seen in 22.4% of tumors
(J:193362)
• mice with tumors containing a Kras mutation show a reduction in latency compared to mice with tumors without a mutation
(J:193362)
• microacinar type tumors show similar expression profiles to human luminal B tumors
(J:193362)
• epithelial-mesenchymal-transition (EMT) subtype tumors have an elevation in the frequency of activating Kras mutations compared to the other types of tumors seen in mutants and show similar expression profiles to human claudin-low tumors
(J:193362)
|
integument
• mammary glands show increased side bud formation at 8 weeks of age
|
• mutants develop mammary tumors
(J:153233)
• nearly 40% of mammary tumors are microacinar, with the remainder of tumors showing various other morphologies including, papillary, squamous, epithelial-mesenchymal-transition (EMT) type, solid, adenocarcinoma and tumors with mixed population of various types of tumors
(J:153233)
• the squamous/EMT subgroup of tumors shares attributes of human triple-negative breast cancer and is associated with an increase in risk of metastasis
(J:153233)
• Kras activating mutations are seen in 22.4% of tumors
(J:193362)
• mice with tumors containing a Kras mutation show a reduction in latency compared to mice with tumors without a mutation
(J:193362)
• microacinar type tumors show similar expression profiles to human luminal B tumors
(J:193362)
• epithelial-mesenchymal-transition (EMT) subtype tumors have an elevation in the frequency of activating Kras mutations compared to the other types of tumors seen in mutants and show similar expression profiles to human claudin-low tumors
(J:193362)
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
breast cancer | DOID:1612 |
OMIM:114480 |
J:193362 |